Wegovy weight loss injections

A quick overview of key details.

Wegovy is a clinically proven, UK licensed weight loss treatment. Clinical trials have shown it can help achieve up to 20% body weight loss. It is a GLP-1 weight loss medication prescribed for people with a body mass index (BMI) over 30. It can also be prescribed for patients with a BMI of 27+ and a weight-related medical condition. The active ingredient semaglutide is manufactured by Novo Nordisk. It is the same active ingredient found in Ozempic, but Wegovy is specifically licensed for weight management.

Wegovy should only be used to support weight loss if lifestyle changes like regular exercise and diet haven't been successful. Other GLP-1 medications are also available in the UK, including Saxenda, Mounjaro and Ozempic. Wegovy can be used for patients who have a BMI of over 30, or in patients with a BMI over 27, and other risk factors such as: Type 2 diabetes High cholesterol Obstructive sleep apnoea High blood pressure

Wegovy (semaglutide) is available on the NHS through specialist weight management services for eligible patients. It may be prescribed if you have weight-related health problems and a BMI of 35 or higher (or 32.5 or higher for people of Asian, Chinese, Middle Eastern, Black African or African-Caribbean origin). In some cases, it may be offered to those with a BMI between 30 and 34.9 (or 27.5 and 32.4 for the above groups) if additional clinical criteria are met. Wegovy has limited availability on the NHS and is primarily prescribed privately for weight loss.

Yes. For example, Simple Online Pharmacy offers Wegovy after a clinician reviews your eligibility through an online consultation.

Prices typically range from £99 to £329 per month, depending on the dose and prescription length.

Alternatives include Saxenda (liraglutide), Orlistat, or Mounjaro (tirzepatide). Consult with your clinician to determine the best option for you.

Clinical trials show an average weight loss of 20% when using the 7.2mg dose combined with diet and exercise.

While Wegovy (semaglutide) has shown great results for weight loss, research shows it might have additional benefits. The SELECT study, conducted worldwide with over 17,000 patients, aimed to demonstrate Wegovy's ability to reduce a patient's chances of experiencing a repeat cardiovascular event (such as a heart attack or stroke). The study appeared to be successful, showing a 20% risk reduction, meaning you are 20% less likely to have a heart attack or stroke if you have had one previously, independent of weight lost. This shows that Wegovy has specific beneficial properties on the heart. This is what sets Wegovy apart from other similar weight loss medications; it has significant evidence to back up its positive impact on reducing the risk of a secondary heart attack or stroke. So, if you have cardiovascular disease, such as a previous heart attack or stroke, and are in two minds as to which weight loss option is for you, this may be a point of difference. If you have any questions about our treatment options and their benefits, please contact our clinical team.

Clinical trials show an average weight loss of 20% when using the 7.2mg dose combined with diet and exercise.

Most users notice appetite suppression within days, while significant weight loss typically begins after 8–12 weeks.

Weight regain is possible without ongoing lifestyle changes such as healthier eating and increased physical activity. Wegovy is intended for long-term use under medical supervision.

Yes, it can reduce risks of heart disease, type 2 diabetes, and improve overall metabolic health.

Wegovy works by mimicking the action of GLP-1, a natural hormone produced in the gut after eating. This hormone plays a key role in appetite regulation. Its main effects are: It helps regulate appetite, making it easier to eat less It slows stomach emptying, making you feel fuller for longer Both actions lead to eating fewer calories, which results in weight loss.

The dosage table below outlines the recommended titration for Wegovy when used for weight loss.

It is administered as a once-weekly subcutaneous injection in the abdomen, thigh, or upper arm.

Begin at 0.25mg per week for 4 weeks, then gradually increase every 4 weeks to a maintenance dose of 2.4mg per week. Patients may also choose to increase their dose further, to 7.2mg per week (given as three 2.4mg doses).

Take the missed dose within 5 days. If more than 5 days pass, skip the missed dose and resume your regular schedule.

No. You must follow the prescribed titration schedule to minimise side effects.

Each Wegovy pre-filled pen contains four once-weekly doses and lasts four weeks. Pens are colour-coded to match your current stage in the titration schedule.

The most common side effects with Wegovy affect the digestive system. These can include things like nausea, vomiting, diarrhoea and constipation. Most patients should see these effects subside after a few days. Other common side effects include: Feeling weak or tired Dizziness Headache Injection site reactions

Common side effects include nausea, vomiting, diarrhoea, constipation, and abdominal pain. These often resolve as the body adjusts to treatment.

Eating smaller meals, avoiding very fatty or rich foods, and staying well hydrated can help. Nausea is most common when starting or increasing your dose and usually eases over time. If it is severe or persistent, speak to your clinician.

Animal studies have linked semaglutide to thyroid tumours. Wegovy should be avoided if you or any family members have a history of medullary thyroid carcinoma or MEN syndrome.

No. Wegovy should not be used during pregnancy, as it may harm the foetus. Treatment should be stopped at least 2 months before a planned pregnancy. Use effective contraception while on treatment.

No. Wegovy is not recommended while breastfeeding. Speak to your clinician before starting or continuing treatment if you are breastfeeding or planning to.

Wegovy has not been shown to reduce the effectiveness of the oral hormonal contraceptive pill. Unlike some other weight loss medicines that require additional barrier contraception during dose changes, this is not necessary with Wegovy.

Wegovy may increase the risk of hypoglycaemia if used with insulin or sulfonylureas. Always inform your clinician of all medicines you are taking before starting treatment.

Moderate alcohol consumption is generally acceptable when using Wegovy. However, excessive drinking may worsen gastrointestinal side effects. It is also worth noting that many alcoholic drinks are calorie-dense, which can hinder your ability to lose weight.

Yes, when prescribed appropriately. It is MHRA-approved but is contraindicated for individuals with a history of medullary thyroid carcinoma, pancreatitis, or those who are pregnant.

Each box of Wegovy contains one pre-filled pen, which provides four once-weekly doses. One pen lasts four weeks of treatment.

Both contain semaglutide, but Wegovy is approved for weight loss at higher doses (up to 2.4mg weekly), while Ozempic is licensed for type 2 diabetes at lower doses.

Unopened pens should be refrigerated at 2–8°C. Once opened, store Wegovy at room temperature (≤30°C) and use within 42 days.

Yes. Keep unopened pens in a fridge (36–46°F / 2–8°C) and use a cool bag or insulated case with gel packs while travelling with Wegovy. Avoid heat or freezing. Once opened, a pen can be kept at room temperature (below 86°F / 30°C) for up to 30 days. Always carry pens in your hand luggage, not checked baggage.